Silver Book Fact

Of the 8 Million older Americans at high risk of developing advanced age-related macular degeneration (AMD), 1.3 million will develop advanced AMD within 5 years.  However the NEI-sponsored Age-Related Eye Disease Study (AREDS) nutritional formula could help 300,000 of those 1.3 million avoid the severe vision loss of advanced AMD over a 5-year period.

Bressler, Neil M., Susan B. Bressler, Nathan G. Congdon, Frederick L. Ferris III, David S. Friedman, Ronald Klein, Anne S. Lindblad, Roy C. Milton, and Johanna M. Seddon. Potential Public Health Impact of Age-Related Eye Disease Study Results: AREDS report no. 11. Arch Opthalmol. 2003; 121(11): 1621-4. http://jamanetwork.com/journals/jamaophthalmology/fullarticle/415852

Reference

Title
Potential Public Health Impact of Age-Related Eye Disease Study Results: AREDS report no. 11
Publication
Arch Opthalmol
Publication Date
2003
Authors
Bressler, Neil M., Susan B. Bressler, Nathan G. Congdon, Frederick L. Ferris III, David S. Friedman, Ronald Klein, Anne S. Lindblad, Roy C. Milton, and Johanna M. Seddon
Volume & Issue
Volume 121, Issue 11
Pages
1621-4
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Multifocal electroretinogram (mFERG) and flicker perimetry show abnormal function in the central macula in early ag-related macular degeneration (AMD) and could enhance monitoring of the disease progression in individuals.  
  • A study on the impact of diet on age-related macular degeneration (AMD) found that those who took the highest amounts of carotenoids, such as lutein and zeaxanthin, had a 43%…  
  • Prescription eye drops could delay or prevent half of glaucoma cases in African Americans.  
  • It has been estimated that monthly use of ranibizumab in individuals with age-related macular degeneration (AMD) would reduce the incidence of legal blindness by 72% and visual impairment by 37%,…  
  • Anti-VEGF Letter Improvement
    An anti-VEGF therapy for DME improved vision by more than 15 letters in approximately 36-51% of participants in a trial.